"Myriad Genetics: Patent Law and Genetic Testing" by Matthew Rimmer

Article

Myriad Genetics: Patent Law and Genetic Testing

European Intellectual Property Review (2003)

Matthew Rimmer, Australian National University College of Law

Abstract

This paper considers the legal challenges to the legal validity of the patents held by Myriad Genetics in respect of genetic testing for breast cancer and ovarian cancer. It argues that broad-based patents on gene sequences and medical diagnostics will have a harmful effect upon access to patient care, genetic research, and the administration of public health care.

Keywords

Patent law,
genetic testing,
inventorship,
novelty,
inventive step,
utility,
European Biotechnology Directive,
ethical objections,
research exemption,
compulsory licensing

Disciplines

Publication Date

January 1, 2003

Citation Information

Matthew Rimmer. "Myriad Genetics: Patent Law and Genetic Testing" European Intellectual Property Review Vol. 25 Iss. 1 (2003)
Available at: http://works.bepress.com/matthew_rimmer/24/